Business
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific team has completed the optimization of a rapid diagnostics test for the quantitative measurement of Ocular Immunoglobulin E (IgE), a biomarker for ocular allergies. The test is a simple, rapid, and non-invasive immuno-chromatographic test that enables the identification of allergic conjunctivitis in one single step. This quantitative test is the only FDA-cleared and reimbursable rapid test for IgE and is of high clinical utility in the confirmation of the presence of active ocular allergens. AXIM acquired the technology for this test and has since been optimizing the test to provide quicker and more accurate results. The test when acquired was a 15-minute test and the development team has been able to miniaturize the test and reduce time to result to seven minutes. “Until recently, few allergy testing options were available for in-office use by primary eye care providers, and we want to be leaders in changing that,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “Because we’ve cut the time of giving the test in half, we can give doctors the opportunity to test double the number of patients every day and, since we will be manufacturing the test in-house, we firmly believe that it has the potential to be a profitable new offering.” Although approximately 40% of the general population experiences allergic conjunctivitis, it is often underdiagnosed and consequently undertreated due to the lack of diagnostic tools. AXIM’s rapid IgE test helps in the assessment of total tear IgE levels and is useful for the clinical diagnosis of allergic conjunctivitis and its severity. The presence of an allergen often mimics the signs and symptoms of Dry Eye Syndrome associated with aqueous deficiency and evaporative dry eye or both.   About AXIM® BiotechnologiesFounded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (D...